UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evaluation of KIR3DL1/KIR3DS1 polymorphism in Behçet’s disease

Genes and immunity, 2016-12, Vol.17 (7), p.396-399

2016

Volltextzugriff (PDF)

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

Annals of internal medicine, 1998-03, Vol.128 (6), p.443

1998

Volltextzugriff (PDF)

PULMONARY ARTERIAL ANEURYSMS IN BEHÇET'S SYNDROME: A REPORT OF 24 CASES

Rheumatology (Oxford, England), 1994, Vol.33 (1), p.48-51

1994

Volltextzugriff (PDF)

Demographic and Clinical Features of Uveitis in Tertiary Centers in Turkey

Ophthalmic epidemiology, 2008-09, Vol.15 (5), p.285-293

2008

Volltextzugriff (PDF)

THU0442 Is behcet’s syndrome getting milder? a retrospective analysis of initial presentation findings throughout 4 decades

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.433

2018

Volltextzugriff (PDF)

Anti‐MHC autoimmunity in Behçet’s disease: T cell responses to an HLA‐B‐derived peptide cross‐reactive with retinal‐S antigen in patients with uveitis

Clinical and experimental immunology, 2000-04, Vol.120 (1), p.162-166

2000

Volltextzugriff (PDF)

AB0558 Biosimilar infliximab for behÇet's syndrome

Annals of the rheumatic diseases, 2017-06, Vol.76 (Suppl 2), p.1246

2017

Volltextzugriff (PDF)

A double-blind trial of depot corticosteroids in Behçet's syndrome

Rheumatology (Oxford, England), 2006-03, Vol.45 (3), p.348-352

2006

Volltextzugriff (PDF)

Relation of protein oxidation parameters and disease activity in patients with Behçet's disease

Clinical laboratory (Heidelberg), 2013, Vol.59 (7-8), p.819

2013

Volltextzugriff (PDF)

FRI0337 Infliximab for sight-threatening and refractory uveitis of behçet’s syndrome

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A488-A488

2013

Volltextzugriff (PDF)

EPIDEMIOLOGY OF BEHÇET'S SYNDROME IN TURKEY

International journal of dermatology, 1996-09, Vol.35 (9), p.618-620

1996

Volltextzugriff (PDF)

Frequency of pathergy phenomenon and other features of Behçet's syndrome among patients with inflammatory bowel disease

Clinical and experimental rheumatology, 2008-07, Vol.26 (4 Suppl 50), p.S91

2008

Volltextzugriff (PDF)

Identification of ERAP1 protein allotypes in the Turkish population and evaluation of their contributions to Behçet's disease risk

Pediatric rheumatology online journal, 2015-09, Vol.13 (S1), p.P14-P14, Article P14

2015

Volltextzugriff (PDF)

CECR1 p.Gly47Arg mutations are not increased in frequency in Turkish Behçet's disease patients compared with healthy controls

Pediatric rheumatology online journal, 2015-09, Vol.13 (S1), p.P64-P64, Article P64

2015

Volltextzugriff (PDF)

AB1308 MYCOPHENOLATE FOR THE TREATMENT OF EYE INVOLVEMENT IN PATIENTS WITH BEHÇET’S SYNDROME

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.1760-1760

2022

Volltextzugriff (PDF)

The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center

Medicine (Baltimore), 2003-01, Vol.82 (1), p.60-76

2003

Volltextzugriff (PDF)

POS0816 DRUG SURVIVAL OF INFLIXIMAB IN BEHÇET’S SYNDROME PATIENTS WITH DIFFERENT TYPES OF INVOLVEMENT

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.697-698

2022

Volltextzugriff (PDF)

Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study

Journal of rheumatology, 2005-01, Vol.32 (1), p.98

2005

Volltextzugriff (PDF)

Biosimilar infliximab for Behçet's syndrome: a case series

Clinical and experimental rheumatology, 2019-11, Vol.37 Suppl 121 (6), p.111

2019

Volltextzugriff (PDF)

POS0819 EMERGENCE OF DE NOVO MANIFESTATIONS DURING INFLIXIMAB TREATMENT IN BEHÇET SYNDROME

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.662-663

2021

Volltextzugriff (PDF)

POS0814 DRUG RETENTION RATE, REASONS FOR DISCONTINUATION AND OUTCOME OF INFLIXIMAB USE IN BEHÇET SYNDROME

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.660-661

2021

Volltextzugriff (PDF)

Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial

British journal of ophthalmology, 1992-04, Vol.76 (4), p.241-243

1992

Volltextzugriff (PDF)

SAT0258 DRUG RETENTION RATE AND PROGNOSIS AFTER DISCONTINUATION OF INFLIXIMAB IN PATIENTS WITH BEHÇET SYNDROME

Annals of the rheumatic diseases, 2020-06, Vol.79 (Suppl 1), p.1071-1072

2020

Volltextzugriff (PDF)

A reassessment of the International Study Group criteria for the diagnosis (classification) of Behçet's syndrome

Clinical and experimental rheumatology, 2001-09, Vol.19 (5 Suppl 24), p.S45

2001

Volltextzugriff (PDF)

FRI0307 An outcome survey of 100 patients with cerebral venous sinus thrombosis due to behÇet's syndrome followed up at a single, dedicated center

Annals of the rheumatic diseases, 2017-06, Vol.76 (Suppl 2), p.603

2017

Volltextzugriff (PDF)

1 – 25 von 70

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(39)

Publikationsform

Sprache

Englisch
(67)
Französisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evaluation of KIR3DL1/KIR3DS1 polymorphism in Behçet’s disease

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

PULMONARY ARTERIAL ANEURYSMS IN BEHÇET'S SYNDROME: A REPORT OF 24 CASES

Demographic and Clinical Features of Uveitis in Tertiary Centers in Turkey

THU0442 Is behcet’s syndrome getting milder? a retrospective analysis of initial presentation findings throughout 4 decades

Anti‐MHC autoimmunity in Behçet’s disease: T cell responses to an HLA‐B‐derived peptide cross‐reactive with retinal‐S antigen in patients with uveitis

AB0558 Biosimilar infliximab for behÇet's syndrome

A double-blind trial of depot corticosteroids in Behçet's syndrome

Relation of protein oxidation parameters and disease activity in patients with Behçet's disease

FRI0337 Infliximab for sight-threatening and refractory uveitis of behçet’s syndrome

EPIDEMIOLOGY OF BEHÇET'S SYNDROME IN TURKEY

Frequency of pathergy phenomenon and other features of Behçet's syndrome among patients with inflammatory bowel disease

Identification of ERAP1 protein allotypes in the Turkish population and evaluation of their contributions to Behçet's disease risk

CECR1 p.Gly47Arg mutations are not increased in frequency in Turkish Behçet's disease patients compared with healthy controls

AB1308 MYCOPHENOLATE FOR THE TREATMENT OF EYE INVOLVEMENT IN PATIENTS WITH BEHÇET’S SYNDROME

The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center

POS0816 DRUG SURVIVAL OF INFLIXIMAB IN BEHÇET’S SYNDROME PATIENTS WITH DIFFERENT TYPES OF INVOLVEMENT

Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study

Biosimilar infliximab for Behçet's syndrome: a case series

POS0819 EMERGENCE OF DE NOVO MANIFESTATIONS DURING INFLIXIMAB TREATMENT IN BEHÇET SYNDROME

POS0814 DRUG RETENTION RATE, REASONS FOR DISCONTINUATION AND OUTCOME OF INFLIXIMAB USE IN BEHÇET SYNDROME

Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial

SAT0258 DRUG RETENTION RATE AND PROGNOSIS AFTER DISCONTINUATION OF INFLIXIMAB IN PATIENTS WITH BEHÇET SYNDROME

A reassessment of the International Study Group criteria for the diagnosis (classification) of Behçet's syndrome

FRI0307 An outcome survey of 100 patients with cerebral venous sinus thrombosis due to behÇet's syndrome followed up at a single, dedicated center

Suchergebnisse filtern